Turku University Hospital is the lead sponsor of 6 current clinical trials in our Sweden, Japan, South Korea and EU (CTIS) registers. 3 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Xenon. The most-studied condition is Olecranon Fracture.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Pilot Study: Effects of CCP Intervention on NICU Environment and Preterm Infants Development
NCT07306000 · ClinicalTrials.gov ↗ · Preterm Infant Development, Preterm Infant Health
|
Not applicable | Recruiting | 2025-12 | Japan, South Korea |
|
Scandinavian Olecranon Research in the Elderly
NCT04401462 · ClinicalTrials.gov ↗ · Olecranon Fracture
|
Not applicable | Recruiting | 2020-10 | Sweden |
|
Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage
NCT04696523 · ClinicalTrials.gov ↗ · Subarachnoid Hemorrhage, Aneurysmal, Cerebral Injury, Cerebral Ischemia
Drug: Xenon |
Phase 2 | Recruiting | 2025-04 | Sweden |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System with Turku University Hospital as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Countries |
|---|---|---|---|
|
A Prospective Diagnostic Trial of Al[¹⁸F]F-NOTA-folate PET in Patients with Suspected Cardiac Sarcoidosis or Infective Endocarditis and Healthy Volunteers (FOL-CARD)
2026-526655-59-00 · Cardiovascular Diseases
|
Phase 1 | Authorised | Finland |
|
The Expression of Fibroblast Activation Protein in Patients with Non-Small Cell Lung Cancer Patients
2025-523965-97-00 · CTIS ↗ · Neoplasms
|
Phase 2 | Authorised | Finland |
|
Post-operative analgesia and spinal block duration following total hip arthroplasties - comparison of single-shot intrathecal ropivacaine, and bupivacaine: a randomized, double blinded controlled study
2025-522358-38-02 · CTIS ↗ · Musculoskeletal Diseases
|
Phase 4 | Authorised | Finland |
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Sweden | 2 | 2 |
| Clinical trials in Japan | 1 | 1 |
| Clinical trials in South Korea | 1 | 1 |
| EU register (CTIS) | 3 | — |
A trial with sites in more than one country appears in each of those registers.
Turku University Hospital is the lead sponsor of 3 current trials on ClinicalTrials.gov in our Sweden, Japan and South Korea registers, and 3 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of its 3 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 1 drug or biological as interventions. The most frequent are Xenon (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.